대한뉴팜

Daehan New Pharm announced on July 29 that it had filed two patents, including one for the antihypertensive drug lacidipine. Lacidipine is an antihypertensive that is taken once a day, convenient to take, and has low tolerance. It is exclusively sold in Korea by the foreign company GlaxoSmithKline (GSK) with annual sales of about 20 billion won. Daehan New Pharm has completed the bioequivalence test for lacidipine and plans to launch it in November 2009. Daehan New Pharm expects to capture 25% of the lacidipine formulation market in 2010, expecting additional sales of around 5 billion won. Daehan New Pharm has also developed and launched "Stopping," a preventative and adjunctive treatment for pig diarrhea, which is a fatal disease in pigs, and has completed a patent application for this treatment adjunct. The market for preventative and adjunctive pig diarrhea treatments for pig farms is estimated to be about 10 billion won, and it is expected that exclusive supply will be possible in the domestic market, where there are currently no specific pig diarrhea adjunctive treatments.

Daehan New Pharm’s operating profit soars in the first quarter Daehan New Pharm announced on the 14th that during the first quarter of 2009, the company recorded sales of 8.8 billion won, operating profit of 920 million won, and net profit of 1.46 billion won. The operating profit and net profit represented year-on-year increases of 900% and 155%, respectively. The sharp rise in operating profit was driven by exports, which reached 2 billion won—an increase of 187% compared to 1.1 billion won in the same period of the previous year. The remarkable growth in exports was attributed to the company’s years of effort to develop overseas markets, which have now borne fruit with a rapid increase in exports to new markets such as Russia and the CIS region. This performance reflects that Daehan New Pharm’s finished pharmaceutical products have met various international quality standards, bringing them closer to global quality benchmarks.

Daehan New Pharm Co., Ltd. launched VenomMaster, a non-antibiotic treatment for bovine mastitis, in October this year, and DCS682, a non-antibiotic growth promoter for pigs and chickens, in November. VenomMaster utilizes bee venom, which contains anti-inflammatory, antibacterial, and immune-boosting properties. Developed as a treatment for mastitis, a common infection among dairy cows in Korea, it is the first veterinary pharmaceutical product of its kind to be introduced domestically. The product was commercialized by applying Daehan New Pharm’s advanced pharmaceutical technology to research data accumulated over many years by the Rural Development Administration’s National Institute of Agricultural Sciences. According to reports from major domestic broadcasters (KBS, MBC, YTN, EBS), VenomMaster demonstrated more than 80% treatment efficacy for mastitis cases without the use of antibiotics. The domestic market for bovine mastitis treatment is estimated to exceed 10 billion won annually, and VenomMaster is expected to secure over 30% of that market in 2009. DCS682 was jointly developed with the Industry-Academic Cooperation Foundation of Chosun University as part of a project organized by the Agricultural R&D Promotion Center (ARPC) under the Ministry for Food, Agriculture, Forestry and Fisheries. The domestic market for growth-promoting antibiotics is estimated to exceed 20 billion won per year, and DCS682, as a growth-promoting antibiotic alternative, is projected to capture more than 30% of this market in 2009. Due to growing antimicrobial resistance concerns, the use of antibiotics as growth promoters in compound feed is scheduled to be legally restricted starting in 2009 (according to MIFAFF Notice No. 2007-83). Advanced countries such as those in Europe and the United States have already implemented similar bans, leading to the development of eco-friendly growth promoters and non-antibiotic immune enhancers. Against this backdrop, Daehan New Pharm’s new products are expected to align with the current well-being trend and grow into major “cash cow” items for the company.

Daehan New Pharm Co., Ltd. (CEO Bae Kun-Woo) successfully completed the GMP inspection conducted by the Ethiopian Ministry of Health in June and received final approval of compliance on July 16. As a result, the company expects to export more than USD 1–2 million worth of finished pharmaceuticals and veterinary medicines annually to Ethiopia in the coming years. Daehan New Pharm has consistently exported veterinary medicines to Ethiopia since 2002, starting with USD 320,000 and maintaining annual exports of USD 400,000–500,000. With this GMP approval, the company has now established a foothold to supply its core human pharmaceutical products, including cephalosporin antibiotics and anticancer drugs, to the Ethiopian market. Although Ethiopia is a developing country, it manages its pharmaceutical regulations in accordance with international standards, including WHO GMP criteria. Therefore, the outcome of this inspection carries significant meaning. Moreover, due to the declining presence of competing supplier nations such as India, Pakistan, and China in the Ethiopian pharmaceutical import market, the company’s export prospects are looking even brighter. Daehan New Pharm currently exports cephalosporin-based pharmaceuticals such as ceftriaxone, ceftazidime, and cefpodoxime to more than 20 countries worldwide, including Vietnam, Pakistan, and Cuba. The company is also actively expanding exports of major products such as streptokinase (a thrombolytic agent), and anticancer drugs including carboplatin, dacarbazine, and dactinomycin. Meanwhile, in November 2007, Daehan New Pharm received the USD 5 Million Export Tower Award at the 44th Trade Day celebration. The company continues to strengthen its overseas partnerships and develop strategic export products with strong market potential, aiming to achieve USD 10 million in annual exports within the next few years.

Daehan New Pharm held its 2008 New Year’s kickoff ceremony on Wednesday, January 2, with all executives and employees in attendance at both the headquarters and the manufacturing plant. During the ceremony at the headquarters, seven employees, including Deputy Manager Kim Jong-seong from the Animal Health Division’s Development and Marketing Department, received recognition awards for exemplary performance. The company adopted the slogan “United for Profit, Committed to Goals with Passion” for the year. In his New Year’s address, President Park Myung-rae expressed his expectation that many challenges would arise in the coming year but emphasized that all employees must achieve the company’s business objectives through thorough planning and strong dedication. Following the ceremony, Executive Director Seol Geun-dong delivered a special lecture for the management team on the topic “Eight Characteristics of Successful People.” Meanwhile, the company had held its year-end closing ceremony separately at both the headquarters and the plant on December 31.

As of November 26, 2007, Mr. Seol Geun-dong was appointed Executive Director in charge of Academic Development and Marketing.

The company will be awarded the 'USD 5 Million Export Tower' at the 44th Trade Day ceremony. The award ceremony will be held on Friday, November 30, 2007 at 10 a.m. in the Swingspace Hall on the 3rd floor of COEX.

As of November 5, 2007, Mr. Ryu Jeong-seok was appointed Director in charge of Business Planning and Finance.

Daehan New Pharm Co., Ltd. 23rd Anniversary Ceremony 1. Date: Saturday, October 20, 2007, 09:00–16:30 2. Venue: Cheongho Human Resources Development Center (located in Hwaseong, Gyeonggi Province) 3. Main Events: Company founding ceremony and sports activities 4. Long-Service Awards (Total of 5 recipients, 10-Year Service Award) 1) Won Hoo-jae, Manager, Quality Control Team, Production Division 2) Kim Young-gil, Assistant Manager, Solid Preparation Team, Production Division 3) Shin Hee-joon, Staff, Facility Team, Production Division 4) Heo Young-soon, Staff, Bio Team, Production Division 5) Kim Soon-hee, Staff, Sales Planning & Management Section, Pharmaceutical Business Division*Award Details: Certificate of merit and a 10-don (approx. 37.5g) pure gold lucky key